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CXCR2 EXPRESSION IN TUMOR CELLS IS A POOR PROGNOSTIC FACTOR AND 
PROMOTES INVASION AND METASTASIS IN LUNG ADENOCARCINOMA 
Erminia Massarelli, MD, PhD 
Supervisory Professor: Jonathan M. Kurie, MD 
CXC chemokine receptor 2 (CXCR2) is a G-protein coupled receptor which mediates 
signaling by binding to CXC chemokines CXCL1-3 and 5-8. In non-small cell lung cancer 
CXCR2 has been studied mainly in stromal cells and is known to increase tumor 
inflammation and angiogenesis. However, there is controversial data in the literature 
about CXCR2 expression in tumor cells and its role in the tumor microenvironment.  We 
hypothesized that tumoral expression of CXCR2 and its ligands promote tumor invasion 
and metastasis in non-small cell lung cancer.  
The effect of CXCR2 expression on tumor cells was studied using stable knockdown 
clones derived from a murine KRAS/p53–mutant lung adenocarcinoma cell line (344SQ) 
with high metastatic potential and an orthotopic syngeneic mouse model and in vitro 
using a CXCR2 small molecule antagonist (SB225002). We showed that in vivo CXCR2 
inhibition by knock-down reduces its invasive ability.  In a murine model of orthotopic 
syngeneic lung adenocarcinoma CXCR2 knock-down 344SQ cell line was found to be 
associated with decreased tumor burden, local and distant metastases.  
In order to translate our preclinical discoveries to human NSCLC, we explored CXCR2 
tumoral immunohistochemical expression in 262 tissue microarrays created from tumor 
specimens of patients with surgically resected stage I-II lung adenocarcinoma and 
correlated it with patient clinic-pathological characteristics including smoking status, 
histological differentiation and survival outcomes. We considered also localization of 
CXCR2 expression in the cytoplasm, membrane and nucleus. High cytoplasmic CXCR2  
iv 
was associated with smoking history, aggressive histological differentiation and worse 
survival. When we screened a publicly available large database of human NSCLC cell 
lines (N=52) and human lung adenocarcinomas (N=442), we found that at the gene 
expression level, CXCL5, a CXCR2-ligand, was the main driver of a cluster of cell lines 
and lung adenocarcinomas with high-risk features, including RAS and MET pathway 
activation, epithelial-to-mesenchimal transition and resistance to epidermal growth factor 
inhibition (i.e., gefitinib). We studied promoter methylation in 70 human non-small cell 
lung cancer cell lines and discovered that CXCL5 was regulated by promoter 
methylation.  
We concluded that the CXCR2 axis may be an important target in smoking-related lung 
adenocarcinoma. 
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INTRODUCTION 
Lung cancer is responsible for over a million of deaths worldwide per year 1. Diagnosis is 
often made at an advanced stage and the 5-years survival remains poor (about 15%) 
with only little progress in the last two decades. Lung cancer histology drives the 
therapeutic decisions and chemotherapy choice.  Small-cell lung cancers and non-small-
cell lung cancers (NSCLC) are the two major histological subtypes2. Lung 
adenocarcinoma, a subtype of NSCLC, represents about 50% of the total number of 
lung cancers. First-line chemotherapy for advanced/metastatic NSCLC consists of 
combination chemotherapy with platinum compounds3. In particular, in non-squamous 
histology, pemetrexed has shown to produce better outcomes than gemcitabine4. 
The discovery of driver molecular alterations, such as EGFR mutations5; 6 and most 
recently ALK-fusion7 predominantly in never-smokers8, has unraveled a new horizon in 
the treatment of lung adenocarcinomas. The concept of “oncogene addiction”9 has 
created the basis for the successful use of targeted therapy of genetic alterations (i.e., 
erlotinib and crizotinib) changing therefore the therapeutic approach to this particular 
subtype of NSCLC10, as cancers harboring these genetic alterations are dependent on 
the expression of these single mutant oncogenes for survival. In the last decade, 
extensive literature has been published on genetic alterations that arise in lung 
adenocarcinoma from never smokers, however little is known about potential targets of 
smoking-related lung adenocarcinoma. Known driving mutations found in lung 
adenocarcinomas from smokers are KRAS and BRAF, however more efforts need to be 
implied to discover novel targets in this setting11. 
The major role of chemokines is to act as a chemoattractant to guide the migration of 
cells. Cells that are attracted by chemokines follow a signal of increasing chemokine 
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concentration towards the source of the chemokine. Chemokines are functionally divided 
in two groups: homeostatic which are constitutively produced in certain tissues and are 
responsible for basal leukocyte migration (CCL14, CCL19, CCL20, CCL21, CCL25, 
CCL27 and CXCL12, CXCL13) and inflammatory which are produced under pathological 
conditions (i.e., on pro-inflammatory stimuli such as IL-1, TNF-alpha, viruses) and 
actively participate in the inflammatory response attracting immune cells to the site of 
inflammation (i.e., CXCL8, CCL2, CCL3, CCL4, CCL5, CCL11, CXCL10)12. Members of 
the chemokine family are divided into four groups depending on the spacing of their first 
two cysteine residues: CC chemokines with 2 adjacent cysteines, CXC chemokines in 
which the two N-terminal cysteines are separated by one amino acid, C chemokines with 
only two cysteines and CXC3C chemokines with 3 amino acids between the two 
cysteines. CXC chemokines have multiple roles in the tumor microenvironment13; 14; 15 
and they are expressed on multiple cells including neutrophils, monocytes, eosinophils, 
mast cells, basophils, lymphocytes, epithelial cells, and endothelial cells16; 17. One of the 
most important functions is to mediate communication between different cells in the 
tumor microenvironment and immune system16. CXC chemokines containing the 
sequence Glu-Leu-Arg (ELR motif) as compared with members that lack these 3 amino 
acids are potent inducers of angiogenic activity as these 3 amino acids appear to be 
important in ligand/receptor interactions on neutrophils18.  
Two G-protein-coupled receptors, CXCR1 and CXCR2, and the Duffy antigen receptor, 
are the three known receptors for these chemokines. Endothelial cells and neutrophils 
express CXCR2 and migrate toward sites of CXCR2 ligand production such as 
inflammatory foci or nascent tumors, thereby promoting angiogenesis and inflammation 
in tumors that express ELR-positive CXC chemokines19; 20; 21; 22. CXCR2 binds CXCL8 
(IL-8), CXCL1, 2, and 3 (GROα, β, and γ), CXCL5 (ENA-78), CXCL6 (GCP2), and 
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CXCL7 (NAP2), whereas CXCR1 binds only to GCP2, NAP2, and IL-8. Chemokine 
receptors associate with G-proteins to transmit cell signals following ligand binding. 
Activation of G proteins, by chemokine receptors, causes the subsequent activation of 
the phospholipase C (PLC) with subsequent activation of the mitogen-activated protein 
(MAP) Kinase pathway activation with induction of chemotaxis, degranulation, release of 
superoxide anions and changes in the avidity of integrins within the cell harboring the 
chemokine receptor23.  
In particular CXCR2 couples to the pertussis toxin-sensitive Gi proteins to stimulate PLC- 
β which ultimately results in hydrolisis of the lipid phosphatidylinositol 4,5-bisphosphate, 
generating diacylglycerol, which activates PKC isoforms, and inositol 1,3,4-triphosphate, 
which releases calcium from intracellular stores. In addition, recently CXCR2 has been 
found to contain specific modular protein interaction domains called PDZ domains that 
may be responsible to nucleate the formation of compartmentalized multiprotein 
complexes that are critical for efficient and specific cellular signaling with scaffold 
proteins24; 25.  
Expression of the ELR+ CXC chemokines in human NSCLC samples correlates with 
worse survival26; 27. Wislez M. et al. showed that CXCR2 ligands are abundant in alveolar 
epithelial cells of lung tumors arising in mice expressing KRASG12D alone and in 
combination with a Tp53 mutation (p53R172H) or Pten deletion28; 29; 30; 31; 32; 33. CXCR2 
neutralization decreased tumor angiogenesis and neutrophilic inflammation and blocked 
the expansion of early alveolar neoplastic lesions in KRASLA1 mice without having direct 
effects on tumor cells, implicating the tumor microenvironment in the anti-tumor effect of 
CXCR2 inhibition33.  
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However, there is controversial data in the literature about CXCR2 expression in tumor 
cells and its role on tumor growth and angiogenesis20; 34; 35; 36; 37. Preclinical models have 
shown that CXCR2 expression can impact cell proliferation, migration, invasion and 
stress-induced apoptosis evasion14; 38; 39; 40; 41. There are missing data, however, about if 
these effects are mediated by a direct effect of CXCR2 expression on cancer cells or by 
an anti-angiogenesis effect20; 39; 42; 43. Pharmaceutical inhibition of CXCR2 is currently 
undergoing clinical development in chronic obstructive pulmonary disease (COPD) to 
counter-act the damaging effects of cigarette smoking that produces inflammation with 
increase in alveolar destruction by neutrophils, goblet cell hyperplasia and pro-
angiogenetic effects17; 44. These compounds therefore may be eventually available to be 
used to target the CXCR2 expression on cancer cells in the future. 
Among the CXCR2 inhibitors, SB225002 (N-(2-hydroxy-4-nitrophenyl)-N′-(2-
bromophenyl)urea) was the first reported potent and selective non-peptide inhibitor of 
CXCR2. It is an antagonist of IL-8 binding to CXCR2 with an IC50 = 22 nM. SB 225002 
showed >150-fold selectivity over CXCR1 and four other chemokine receptors tested. 
This compound inhibited the binding of both CXCL8 and CXCL1 on recombinant and 
native CXCR2 and also blocked CXCL8 and CXCL1-induced chemotaxis and 
margination of human and rabbit neutrophils without having any affinity or activity on 
CXCR145. 
To clarify the effect of CXCR2 inhibition in NSCLC, I hypothesized that CXCR2 ligands 
promote tumor invasion and metastasis in NSCLC. I proposed to test this hypothesis by 
investigating the CXCR2 role in a KRAS/p53−mutant lung adenocarcinoma murine 
model in vitro and in vivo46; 47; 48. To understand the potential translational significance of 
my work in human NSCLC, CXCR2 tumoral expression was assessed in tissue 
microarrays of human NSCLC from stage I-II patients in correlation with patients 
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clinicopathological characteristics and a systematic analysis of gene expression profiles 
of CXCR2 and its ligands (subsequently called the CXCR2 axis) was conducted in 
human NSCLC cell lines and lung adenocarcinomas.  
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MATERIALS AND METHODS 
This thesis is based upon the following article: Massarelli E. and Saintigny P, Lin S, 
Ahn Y-H, Chen Y, Goswami S, Erez B, O’Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, 
Berhens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, 
Hong WK, Kurie JM.  Cancer Research. 2013 Jan 15; 73(2):571-82. DOI: 
10.1158/0008-5472. This material is reprinted by permission from the American 
Association for Cancer Research. 
Human lung tissues and tissue microarray 
A detailed description of the tissue microarray (TMA) construction is provided 
elsewhere49. In summary, after histological examination of NSCLC specimens, 
the NSCLC TMAs were constructed by obtaining three 1-mm in diameter cores 
from each tumor at three different sites (periphery, intermediate and central 
tumor sites). 
Immunohistochemical analysis 
Mouse monoclonal anti-human CXCR2 antibody (R&D Systems, Minneapolis, 
MN) was used at a dilution of 1:200, according to the manufacturer’s instruction. 
CXCR2 staining was examined using light microscopy by a lung cancer 
pathologist (Dr. Yuan Ping). An independent observer (Dr. Ignacio I. Wistuba) 
reviewed one third of the cores chosen randomly. In case of discordance (~10%), 
both pathologists reviewed the slides jointly in a multiheaded microscope and 
reached consensus. Both pathologists were blinded with respect to the patients’ 
outcome. Only cytoplasmic CXCR2 expression was quantified using a four-value 
intensity score (0, 1+, 2+, and 3+) and extent of reactivity (0-100%). Final score 
was then obtained by multiplying the intensity and reactivity extension values 
(range, 0-300). 
Animal husbandry 
All animal experiments were reviewed and approved by the Institutional Animal 
Care and Use Committee at MD Anderson Cancer Center. For syngeneic tumor 
experiments, 10- to 16- week-old 129/Sv mice were injected with the indicated 
numbers of tumor cells into the left lung and euthanized at the first signs of 
morbidity. 
Establishment of murine lung adenocarcinoma cell lines 
The methods used to establish lung adenocarcinoma cell lines in culture from 
murine tumors have been described previously46. Cell lines were named 
according to the mouse number and site of derivation (e.g., 344SQ for mouse 
344, subcutaneous metastasis). These cells have alveolar type II cell properties 
and variable propensities to undergo the epithelial-to-mesenchymal transition 
and metastasize following injection into syngeneic mice46; 48. 
RNA extraction and quantitative reverse-transcription PCR 
RNAs were extracted using TRIzol (Invitrogen, Carlsbad, CA). mRNA was 
reverse transcribed using the SuperScript First-Strand Synthesis System 
(Invitrogen). For quantitative PCR reactions, 1:10 dilutions of cDNA products 
were amplified by using SYBR Green PCR Master Mix (Applied Biosystems, 
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Carlsbad, CA) and analyzed by using ABI Prism 7500 Fast System (Applied 
Biosystems). mRNA expression values were normalized on the basis of L32 
mRNA. 
Generation of shRNA transfectants 
The shRNA retroviral CXCR2 constructs were purchased (OriGene, Rockville, 
MD). The sequences of the CXCR2 and scrambled shRNA were as follow: 
CAAGGTGGATAAGTTCAACATTGAAGATT (CXCR2 clone 1), 
GTCTGCTATGAGGATGTAGGTAACAATAC (CXCR2 clone 3), and 
GCACTACCAGAGCTAACTCAGATCGTACT (scrambled shRNA). Purified 
plasmids (1 μg of each) were transfected into 344SQ cells by using 
LipofectAmine and PLUS (Invitrogen). After 48 hours, transfectants were replated 
in RPMI 1640 medium containing 10% FBS and 15 μg/ml puromycin for selection 
and passed serially for 4 weeks to generate stable transfectants. 
Cell invasion assay 
As described previously46, cells (cancer-associated fibroblasts) were seeded first 
in the lower chambers (105 cells), and tumor cells (344SQ) were then seeded in 
the upper chambers (5x104) of 24-well Transwell invasion plates (BD 
Biosciences, Bedford, MA) in serum free medium containing mitomycin C to 
block proliferation. Cells in the upper chambers were allowed to invade for 14 to 
16 hours. Cells on the inserts were fixed with 90% ethanol, stained with 0.1% 
crystal violet blue, and washed with ddH2O. Noninvaded cells on the upper side 
of the inserts were wiped off with a cotton swab. Invaded cells were counted in 
five microscopic fields at 4x magnification, and the counts were averaged. A 
small molecule antagonist of CXCR2 (SB225002)  (Calbiochem) was used to 
inhibit CXCR2 invasive properties of 344P cells in Boyden chamber assays and 
included 344SQ cells as positive controls45; 50. 
Gene expression analysis 
Publicly available gene expression profiles and clinical annotations of 442 lung 
adenocarcinomas were downloaded from the NCI Director’s Challenge 
Consortium for the Molecular Classification of adenocarcinoma (DCC)51. CEL 
files of 52 NSCLC cell lines (GSE4824)52; 53, 130 lung squamous cell carcinomas 
with clinical annotations (GSE4573)54, and 7 NSCLC cell lines and 3 human 
bronchial epithelial cell lines (HBEC) before and after treatment with 5-aza-2'-
deoxycytidine (decitabine) (GSE5816)55 were downloaded from Gene Expression 
Omnibus (GEO). The gene expression analysis was generated by using Array 
Studio software (Omicsoft Corporation, Research Triangle Park, NC). Raw 
microarray data were processed using quantile normalization and robust multi-
array average algorithm. Probesets corresponding to CXCR2 axis were identified 
using the NetAffx Analysis Center from Affymetrix website. They were used to 
compute an unsupervised hierarchical clustering of the cell lines and of the lung 
adenocarcinomas using the Pearson's correlation coefficient and Ward's linkage 
method. To summarize the effect of CXCR2 axis, a principal component analysis 
was computed with the first two components. In the DCC, the first principal 
component (PC1) was used for correlative studies with tumor differentiation, 
smoking status, and overall survival. In the cell lines, PC1 was correlated with the 
whole genome. Gene Set Enrichment Analysis (GSEA) using the “pre-ranked” 
tool was done using either the genes ranked according to their correlation with 
PC1, or to fold-change between groups defined by the unsupervised hierarchical 
clustering. Probesets with an absolute Pearson correlation or a fold-change ≥0.5 
were included in network analyses performed using Ingenuity Pathway Analysis 
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(IPA) (Ingenuity® Systems, Redwood City, CA). Details of the GSEA and IPA are 
provided in Supplementary Material and Methods. 
CXCL5 promoter methylation study 
CXCL1, CXCL2, CXCL3, CXCL5 and CXCL6 promoter methylation status was 
obtained from high-throughput promoter methylation profiles of 42 NSCLC cell 
lines overlapping with the panel of 52 NSCLC cell lines analyzed for gene 
expression. CXCL7 and CXCL8 results did not pass the quality control and were 
not included in the analysis. DNA methylation status of a set of 27,579 CpG sites 
around promoters of 14,475 consensus coding sequences was interrogated 
using the Illumina HumanMethylation27 Beadchip (Illumina, Inc., San Diego, CA). 
Genomic DNA (1 μg) was bisulfite-converted using the EZ DNA Methylation kit 
(Zymo Research Corp, Orange CA). Whole-genome amplification, fragmentation, 
hybridization, washing, counterstaining, and scanning were performed according 
to the manufacturer’s instructions. The scanner data and image output files were 
managed with the Illumina BeadStudio software Methylation module v.3.2. The 
normalized data, presented as beta values, represent the degree of methylation 
at each CpG site, 0 being unmethylated and 1 being methylated.  
Gene Set Enrichment Analysis 
GSEA is a robust computational method that determines whether an a priori 
defined set of genes shows statistically significant, concordant correlation with 
the CXCR2/CXCR2 ligands biological axis. GSEA aims to interpret large-scale 
expression data by identifying pathways and processes56. The main advantage of 
this method is its flexibility in creating molecular signature databases of gene 
sets, including ones based on biologic pathways, or expression profiles in 
previously generated microarray data sets. The input data for the GSEA56 were 
the following: (1) a complete table of genes ranked according to their Pearson 
correlation with PC1, (2) a mapping file for identifying probesets in HG-U133A 
and B platforms, and (3) a catalog of functional gene sets from Molecular 
Signature Database (MSigDB, version 3.0, 30-September-2010 release, 
www.broad.mit.edu/gsea/msigdb/msigdb_index.html). A total of 2,480 curated 
gene sets (canonical pathway gene sets, chemical and genetic perturbations 
gene sets, BioCarta gene sets, GenMAPP gene sets, and KEGG gene sets) 
were included in the analysis. Default parameters were used. Probesets (44,754 
unique features in cell lines, 22,283 unique features in lung adenocarcinomas) 
were collapsed into gene symbols (18,770 unique genes in cell lines, 13,321 
unique genes in lung adenocarcinomas). Inclusion gene set size was set 
between 15 and 500, and the phenotype was permutated 1,000 times. Gene sets 
that met the false discovery rate 0.25 criterion were considered. 
Ingenuity Pathway Analysis 
Probesets with an absolute Pearson correlation or a fold-change equal to or 
greater than 0.5 were included in network analyses performed using Ingenuity 
Pathway Analysis (Ingenuity® Systems, www.ingenuity.com). Network 
Generation: a data set containing gene identifiers and corresponding expression 
values was uploaded into in the application. Each gene identifier was mapped to 
its corresponding gene object in the Ingenuity Pathways Knowledge Base. These 
genes, called focus genes, were overlaid onto a global molecular network 
developed from information contained in the Ingenuity Pathways Knowledge 
Base. Networks of these focus genes were then algorithmically generated based 
on their connectivity. Network/My Pathways Graphical Representation: a 
Network/My Pathways is a graphical representation of the molecular 
relationships between genes/gene products. Genes or gene products are 
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represented as nodes, and the biological relationship between two nodes is 
represented as an edge (line). 
All edges are supported by at least one reference from the literature, from a 
textbook, or from canonical information stored in the Ingenuity Pathways 
Knowledge Base. Human, mouse, and rat orthologs of a gene are stored as 
separate objects in the Ingenuity Pathways Knowledge Base, but are 
represented as a single node in the network. The intensity of the node color 
indicates the degree of positive (red) or negative (green) correlation. Nodes are 
displayed using various shapes that represent the functional class of the gene 
product. Edges are displayed with various labels that describe the nature of the 
relationship between the nodes. 
Statistical analysis 
Wilcoxon rank sum test or Kruskal-Wallis test was used to test the differences of 
CXCR2 expression between/among categorical variable levels. Martingale 
residuals were performed from a Cox model that included only baseline hazard 
function but no covariate. By applying a nonparametric smoother, the plots allow 
one to examine visually the nature of the relationship between the residuals and 
CXCR2 H-scores and to define a reasonable cutoff point to dichotomize the 
population. The Kaplan-Meier method was used to construct overall and 
recurrence-free survival curves, and the log-rank test was used to test the 
difference by covariate levels. Univariate and multivariate Cox models were fitted 
to estimate the effect of prognostic factors, including patient age, sex, tumor 
histology, stage, and marker on time to event endpoint. For cell line experiments, 
comparisons between two groups were performed using the Wilcoxon rank sum 
test unless otherwise indicated. One-way ANOVA was performed to compare 
multiple experimental groups. All statistical tests were two-sided, and P-values of 
0.05 or less were considered to be statistically significant.  
RESULTS 
 
Creation of an orthotopic syngeneic lung adenocarcinoma metastasis 
model 
We recently described the creation of a panel of cell lines from 
KrasLA1/+p53R172HΔG/+ mice, which develop aggressive and metastatic lung 
adenocarcinoma48. One of these cell lines, 344SQ, is highly metastatic when 
injected subcutaneously into syngeneic mice46. In order to refine our lung 
adenocarcinoma metastasis model, we used 344SQ to create a novel orthotopic 
syngeneic model. As previously described57, 2x104 344SQ cells were injected 
into the left lung of syngeneic mice. The mice were euthanized 21 days after 
injection and, at necropsy, had developed metastases to hilar and mediastinal 
lymph nodes (Fig. 1), chest wall, and controlateral lung as well as extrathoracic 
distant metastases in the paraaortic lymph nodes, liver, adrenal glands, kidneys, 
spleen and diaphragm.   
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Figure 1. Mediastinal lymph node metastasis from an orthotopic lung tumor. 
Hematoxylin and eosin-stained tissue section of a mediastinal lymph node from a 
mouse injected intrathoracically (left lung) with 344SQ cells (2x104), killed after 21 
days, and subjected to necropsy (L: lymphocytes; TC: tumor cells) 
 
CXCR2 knockdown decreased tumor cell invasion in vitro 
To investigate the role of CXCR2 expression by tumor cells, we created CXCR2 
shRNA clones from parental 344SQ lung adenocarcinoma cell lines isolated from 
KrasLA1/+p53R172HΔG/+ mice. CXCR2 shRNA clones exhibited significantly 
lower expression of CXCR2 mRNA than scrambled controls (Fig. 2A). To test the 
invasion potential of the shRNA clones, we used cocultures with cancer-
associated fibroblasts, which produce high levels of CXCR2 ligands, as 
previously described58. To block tumor cell proliferation, we added mitomycin C 
to the serumfree medium in which the tumor cells were cultured (344SQ). 
CXCR2 shRNA clones showed a significantly lower invasion potential than 
scrambled controls (Fig. 2B). 
CXCR2 pharmacological inhibition decreased tumor cell invasion in vitro 
To confirm our findings in the 344SQ cells, we carried out experiments by using 
344P, a second highly invasive and metastatic lung adenocarcinoma cell line 
derived from KrasLA1/+p53R172HΔG/+mice. To inhibit CXCR2 using a different 
approach, we used a small molecule antagonist of CXCR2, SB225002, that has 
demonstrated selectivity and potency in vitro and in vivo45; 50. We examined the 
effect of SB225002 on 344P cell invasive properties in Boyden chamber assay 
and included 344SQ cells as a positive control. Treatment with SB225002 
Figure 1 
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inhibited tumor cell invasive properties with as IC50 of 3-4 μmol/Lfor both 344P 
cells and 344SQ cells (Fig. 2C-D). 
CXCR2 knockdown in tumor cells decreased 344SQ metastatic potential 
We used the orthotopic murine model already described to test whether the 
metastatic potential of 344SQ would be affected by CXCR2 knockdown. Two 
shRNA clones (clone-1 and clone-3) and scrambled controls were compared by 
injecting 2x104 cells into the left lung of mice (N=10 in each group, for a total of 
30 mice). Mice were euthanized at 21 days after injection because two of the 10 
mice in the scrambled control group demonstrated poor physical conditions due 
to tumor burden. At necropsy, mice bearing CXCR2-shRNA lung 
adenocarcinoma had significantly fewer lung tumor nodules in the lung of primary 
injection (Fig.2E) and fewer distant metastases (Fig. 2F) than scrambled 
controls. Sites of distant metastases included liver, adrenal glands, ipsilateral and 
controlateral lung, diaphragm, spleen and paraortic lymph nodes.  
 
Figure 2. Effect of CXCR2 downregulation and inhibition. In vitro (A-B) properties of 
shRNA clones (clone-1 and -3) compared to scrambled control: (A) mRNA expression by 
reverse transcription PCR relative to standard, (B) invasion assay using co-cultures with 
cancer associated fibroblasts (CAF) and mitomycin C to block tumor cell proliferation. In 
vitro CXCR2 inhibition with CXCR2-antagonist (C, D): invasion assay using co-cultures 
of 344P (C) and 344SQ (D) cell lines treated with increasing concentrations of 
SB225002.In vivo properties of shRNA clones (clone-1 and -3) compared to scrambled 
control (E, F): number of left lung tumor nodules, (E) number of distant metastases (F). 
Median and inter-quartile range are shown in the dot plots (E, F). Wilcoxon rank sum test 
(A, B, E, and F) between scrambled control and shRNA single clones (clone-1 and 
clone-3) or between different concentrations of SB225002and the control (C, D).  
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CXCR2 protein expression in human NSCLC tumor cells is associated with 
adverse outcome and tobacco smoking 
To investigate the role of CXCR2 in human tumor cells, we stained a tissue 
microarray that included 370 resected NSCLC. For the purpose of this study, we 
considered only 262 patients with stage I and II disease who did not receive 
preoperative chemotherapy. Clinical and pathological characteristics of the 
patient population are described in Table 1. Median age was 67.4 years (range: 
32.2-90.0). Adenocarcinoma was the most frequent histological subtype (N=173, 
66%). With a median follow-up of 5.3 years, 133 patients had developed 
recurrence (50.8%) and 101 had died (38.5%).  
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Table 1. Clinical and pathological characteristics of patients included in the tissue 
microarray (N=262).  
 
CXCR2 was expressed mainly in the cytoplasm (mean 31.07±30.78, median 20, 
range 0-130). Distribution of cytoplasmic CXCR2 protein expression in the whole 
population is shown in Fig. 3.  
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Figure 3. Distribution of cytoplasmic CXCR2 protein expression. Distribution of 
cytoplasmic CXCR2 protein expression in 262 non small cell lung cancer cell lines by  
squamous cell carcinoma (SCC) and adenocarcinoma (Adeno) histology. 
 
Figure 4 shows one adenocarcinoma and one squamous cell carcinoma 
expressing CXCR2 with an intensity of 1 in 100% of tumor cells, and an H-score 
of 100. CXCR2 expression was low in the nucleus (mean 16.15±24.88, median 
3.33, range 0-120). Cytoplasmic and nuclear CXCR2 expression levels were not 
correlated (rho=-0.02, P=0.76). No association was observed between 
cytoplasmic CXCR2 and patient sex, race, tumor histology, stage or degree of 
inflammation. Cytoplasmic CXCR2 expression was higher in current smokers 
(32.57±28.28) and former smokers (31.19±33.15) than in never smokers 
(25.28±29.00), although it did not reach statistical significance. Similarly, poorly 
differentiated tumors had higher cytoplasmic CXCR2 levels (39.84±32.20) than 
moderately (29.99±30.18) or well-differentiated (16.46±23.98) tumors 
(P<0.0001).  
Figure 3 
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Figure 4. Expression of CXCR2 in tumor cells and tissues. Immunohistochemical 
expression of CXCR2 in two NSCLC tissue specimens, (A) squamous cell carcinoma 
and (B) adenocarcinoma.  
 
 
The Martingale residual plots showed that median CXCR2 H-score was a 
reasonable cutoff point (Fig. 5).  
  
Figure 4 
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Figure 5. Median CXCR-2 immunohistochemistry score. Martingale residuals 
analysis from a Cox model that includes only baseline hazard function but no covariate, 
are represented on the vertical axis and CXCR2 H-scores (CXCR2c) are represented on 
the horizontal axis. The median H-score for CXCR2 expression is shown by a vertical 
bar.  
 
 
 
 
When cytoplasmic CXCR2 level was dichotomized using the median expression 
of 20, 141 (53.8%) tumors expressed low CXCR2 levels (<=20) and 121 (46.2%) 
tumors expressed high CXCR2 levels (>20). EGFR and KRAS mutational status 
was available for 157 of the lung adenocarcinomas; Figure 6 shows that  
cytoplasmic CXCR2 protein expression was lower, although not reaching 
statistical significance, in EGFR-mutant lung adenocarcinomas (N=17, mean 
24.71±29.49, median 13.33, range 0-90), which are known to be more frequent 
among never smokers, than in KRAS-mutant (N=41, mean 31.02±31.65, median 
20, range 0-110) or wild-type EGFR and wild-type KRAS lung adenocarcinomas 
(N=99, mean 33.05±33.61, median 20, range 0-130), which are more frequent 
among smokers. 
 
 
 
Figure 5 
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Figure 6. CXCR2 expression according to EGFR and KRAS mutation status. 
CXCR2 expression in tumor cells according to EGFR and KRAS mutation status. EGFR 
and KRAS mutation status was available for 157 lung adenocarcinomas analyzed for 
cytoplasmic CXCR2 protein expression.  
 
 
  
Figure 6 
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Using Kaplan-Meier curves, high CXCR2 expression was associated with poor 
overall survival and recurrence-free survival in patients with lung 
adenocarcinoma, although not reaching statistical significance (Fig. 7A-B).  
 
Figure 7. Overall survival and recurrence-free survival as a function of 
cytoplasmic CXCR2 expression in lung adenocarcinoma. Kaplan-Meier 
curves for (A) overall survival and (B) recurrence-free survival as a function of 
cytoplasmic CXCR2 expression in 173 patients who underwent resection for lung 
adenocarcinoma.  
 
 
No such association was observed in patients with squamous cell carcinoma 
(Fig. 8A-B).  
  
Figure 7 
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Figure 8. Overall survival and recurrence-free survival as a function of 
cytoplasmic CXCR2 expression in lung adenocarcinoma. Kaplan-Meier curves for 
(A) overall survival and (B) recurrence-free survival as a function of cytoplasmic CXCR2 
protein expression in 89 patients who underwent resection for lung squamous cell 
carcinoma.  
 
 
Univariate Cox proportional hazards model assessed the effect of covariates on 
survival. High CXCR2 expression was associated with worse overall survival in 
both subtypes [hazard ratio (HR) =1.488 95% confidence interval (95%CI): 
0.905-2.448; HR=1.520 95%CI: 0.798-2.894] (Table 2A and 3A), although not 
reaching statistical significance. For recurrence-free survival, a similar trend was 
observed in adenocarcinoma (HR=1.284 95%CI: 0.830-1.985), but not in 
Figure 8 
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squamous cell carcinoma (HR=1.028 95%CI 0.593-1.782) (Table 2B and Table 
3B).  
 
 
Table 2. Univariate Cox model assessing the effect of covariates on overall survival (A) 
and recurrence-free survival (B) (M: male; F: female; HR: hazard ration; 95CI: 95% 
confidence interval), in adenocarcinoma patients (N=173).  
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Table 3. Univariate Cox model assessing the effect of covariates on overall survival (A) 
and recurrence-free survival (B) (M: male; F: female; HR: hazard ration; 95CI: 95% 
confidence interval), in squamous cell carcinoma patients (N=89).  
 
 
Final multicovariate Cox models are presented in Table 2. Combining all patients 
together, after adjusting for patients’ age, sex, and tumor stage, high cytoplasmic 
CXCR2 expression remained associated with poor overall survival (HR=1.559; 
95%CI: 1.051-2.312, P=0.0273) (Table 4A). 
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Table 4. Final multicovariate Cox models assessing the effect of covariates on overall 
survival in the whole population (N=262), in patients with lung adenocarcinoma 
(N=173) (B), and in patients with lung squamous cell carcinoma (N=89) (C) (M: male; 
F: female; HR: hazard ration; 95CI: 95% confidence interval). 
 
 
Gene expression pattern of CXCR2 axis is associated with human smoking-
related adenocarcinoma and adverse clinical features 
High-throughput gene expression profiles offer the opportunity to study CXCR2 
as well the genes that encode for its known ligands. We took advantage of 
publicly available profiles of 52 NSCLC cell lines and 442 early stage resected 
lung adenocarcinoma. Gene expression patterns of CXCR2 ligands in NSCLC 
cell lines and lung adenocarcinoma were comparable (Fig. 9). Unsupervised 
hierarchical clustering using the CXCR2 axis identified a cluster of cell lines with 
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high expression of CXCR2 ligand genes, which we called the CXCR2/CXCR2 
ligands cluster, that included nine (17%) of the cell lines analyzed (Fig. 9A). 
This group was enriched in KRAS mutations (Fisher’s exact test, P=0.0548). 
HCC827, an EGFR-mutant cell line with an exon 19 deletion, was also part of 
this group. In lung adenocarcinomas, a similar cluster of 115 (26%) tumors was 
identified (Fig. 9B). EGFR mutation status was available for 170 
adenocarcinomas. None of the 30 tumors included in the CXCR2/CXCR2 ligands 
cluster harbored EGFR mutations, whereas 24 of the remaining 140 
adenocarcinomas did harbor an EGFR mutation (Fisher’s exact test, P=0.0295). 
A similar CXCR2/CXCR2 ligands cluster was observed in each of the four 
individual cohorts forming the DCC (data not shown). From Massarelli E. and 
Saintigny P., Cancer Res. 2013 Jan 15; 73(2):571-82. DOI: 10.1158/0008-5472. 
 
Figure 9. Distribution of expression of CXCR2, its ligand genes and IL8 in non-
small cell lung cancer cell lines and lung adenocarcinomas. Distribution of 
expression of CXCR2 and its ligand genes (CXCL1,CXCL2, CXCL3, CXCL5, CXCL6, 
PPBP [CXCL7], and IL8 in non-small cell lung cancer cell lines (panel A; N=52) and lung 
adenocarcinomas (panel B; N=442).  
 
 
A trend toward a worse prognosis in the high CXCR2/CXCR2 ligands cluster was 
observed (Fig. 10A). Using a similar approach in 130 patients resected for 
squamous cell carcinoma and included in the GEO series GSE457354, we did 
not see any association between high CXCR2/CXCR2 ligands cluster and poor 
outcome (Fig. 10B,C). 
Figure 9 
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Figure 10. CXCR2/CXCR2 ligands association with overall survival in patients with 
lung adenocarcinoma. CXCR2/CXCR2 ligands cluster is associated with a worse 
overall survival in patients with lung adenocarcinoma (N=442) (A). CXCR2/CXCR2 
ligands cluster is not associated with outcome in patients with lung squamous cell 
carcinoma (N=130) (B, C).  
 
Figure 10 
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In both cell lines and lung adenocarcinoma, we compared the genes differentially 
expressed between the CXCXR2/CXCR2 ligands cluster and the remaining 
samples across the whole genome. In both cases, CXCL5 gene was the most 
frequently upregulated in the CXCR2/CXCR2 ligands cluster. Members of the 
aldo/keto reductase superfamily (AKR1B10, AKR1C2, AKR1C3), associated with 
tobacco exposure, were also upregulated. In cell lines, TGFB1, vimentin (VIM), 
and osteopontin (SPP1) were upregulated in the CXCR2/CXCR2 ligands cluster, 
while desmoplakin (DSP) and hepatocyte growth factor activator inhibitor 1 
(SPINT1) were downregulated. These changes may be associated with the 
epithelial-to-mesenchymal transition and promote invasion and metastasis. In 
lung adenocarcinomas, genes encoding the matrix metalloproteinases were 
upregulated in the CXCR2/CXCR2 ligands cluster, as was the dual specificity 
phosphatase 4 (DUSP4) gene, which is known to be downregulated in EGFR-
mutant NSCLC. Consistent with the association between poor differentiation and 
CXCR2 protein expression observed in the tissue microarray, another striking 
change was the downregulation of differentiation-associated genes, including 
thyroid transcription factor 1 (NKX2-1) (Fig. 11A) and surfactant proteins B 
(SFTPB), C (SFTPC), and D (SFTPD), in the CXCR2/CXCR2 ligands cluster. 
Interestingly, ribonucleotide reductase M2 (RRM2) was upregulated in the 
CXCR2/CXCR2 ligands cluster, while folic acid receptor 1 (FOLR1) was 
downregulated. RRM2 and FOLR1 have been reported to modulate response to 
gemcitabine and pemetrexed, respectively, in NSCLC. Similar trends were 
observed in cell lines for FOLR1 and NKX2-1 downregulation (Fig. 11B). 
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Figure 11. TTF-1 gene expression in lung adenocarcinomas and cell lines. TTF-1 
gene expression was more frequently lower in lung adenocarcinomas (A) and cell lines 
(B) included in the CXCR2/CXCR2 ligands cluster.  
 
Figure 11 
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The most significant network associated with differential gene expression, with 
an absolute fold-change ≥0.5 between the CXCR2/CXCR2 ligands cluster and 
the remaining samples, was related to NFKB in both the cell lines and lung 
adenocarcinoma (data not shown). Using as input the fold-change in gene 
expression between the CXCR2/CXCR2 ligands cluster and the remaining lung 
adenocarcinomas, GSEA showed enrichment of genes associated with poor 
survival (Fig. 12C) (28). We also found enrichment in gene sets associated with 
poor differentiation and proliferation (data not shown), as well as MET 
transcriptionally co-regulated genes (Fig. 12D). Using as input the fold-change in 
gene expression between the CXCR2/CXCR2 ligands cluster and the remaining 
cell lines, GSEA showed a significant upregulation of gene sets related to the 
RAS pathway (Fig. 12E) and resistance to gefitinib (Fig. 12F), and enrichment of 
target genes of hsa-miR-let7, a known regulator of KRAS expression, and of 
genes associated with the epithelial-to-mesenchymal transition was observed 
(data not shown). 
 
Figure 12. Identification of a CXCR2/CXCR2 ligands cluster. Unsupervised clustering 
using gene expression of CXCR2 and its ligands (CXCL6, IL8, CXCL2, CXCL1, CXCL3, 
PPBP [CXCL7], and CXCL5) in (A) 52 NSCLC cell lines and (B) 442 lung 
adenocarcinomas. For Gene 23 Set Enrichment Analysis, genes were preranked 
according to the fold-change observed between samples with the CXCR2/CXCR2 
ligands cluster and the remaining samples in both lung adenocarcinomas (C, D) and cell 
lines (E, F); representative gene sets enriched with a P-value and a false discovery rate 
<0.0001 are shown for lung adenocarcinomas (C, D) and NSCLC cell lines (E, F).  
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As an alternative approach to studying the effect of the CXCR2/CXCR2 ligands 
axis, we summarized the effect of this axis by computing a principal components 
analysis (Fig. 13A and 14A). The distribution of PC1 in cell lines was bimodal, a 
group of 12 cell lines having a high PC1 (≥1.5) and the remaining cell lines 
having a low PC1 (Fig. 13B). Interestingly, cell line H1395, which has been 
reported to harbor an inactivating CXCR2 G354W mutation, had a low PC1 (Fig. 
13B). Cell lines included in the CXCR2/CXCR2 ligands cluster or with a high PC1 
had low levels of NKX2-1 gene expression, except HCC827 (Fig. 13C). 
 
 
Figure 13. Expression of CXCR2 and its ligand genes in NSCLC cell lines. The first 
two principal components were computed using expression of CXCR2 and its ligand 
genes (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, PPBP [CXCL7], and IL8) in 52 
NSCLC cell lines. (A) The first principal component (PC1) accounted for 48.25% of the 
variation of the principal components analysis and allowed identification of two groups of 
cell lines (bimodal distribution). (B) Cell lines with a high PC1 had a significant overlap 
with cell lines included in the CXCR2/CXCR2 ligands cluster. (C) TTF-1 gene expression 
was low in almost all the cell lines with high PC1 outlined by the blue box. NCI-H1395 
(shown by a star) has an inactivating CXCR2 G354W mutation.  
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In lung adenocarcinomas, a similar bimodal distribution of PC1 was observed 
(Fig. 14A). Consistently with our immunohistochemical results, PC1 was 
statistically significantly higher in poorly differentiated adenocarcinomas than in 
moderately (P=0.0065) and well-differentiated tumors (P=0.0006) (Fig. 14B), and 
higher in current smokers than in former (P=0.0010) and never smokers 
(P=0.0085) (Fig.14C).  
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Figure 14. Expression of CXCR2 and its ligand genes in lung adenocarcinomas. 
The first two principal components were computed using expression of CXCR2 and its 
ligand genes (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, PPBP [CXCL7], and IL8) in 444 
lung adenocarcinomas. (A) The first principal component (PC1) accounted for 46.15% of 
the variation of the principal component analysis in lung adenocarcinomas. (B) PC1 was 
statistically higher in poorly differentiated versus moderately (P=0.0065) or well 
differentiated (P=0.0006) lung adenocarcinomas and (C) in current versus former 
(P=0.0010) or never smokers P=0.0085.  
 
 
Figure 14 
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When PC1 was dichotomized based on the median, tumors with low PC1 linked with 
longer OS (Fig. 15); low PC1 was associated with HR of 0.6907 (95CI: 0.5302-0.9000, 
Pvalue= 0.0061). After adjusting for patient age, sex, tumor stage, and institution, low 
PC1 remained associated with longer overall survival (HR of 0.6827; 95CI: 0.5046-
0.8701,P=0.0031) (Fig 15).  
Figure 15. PC1 and overall survival.  
 
 
CXCL5 is the main driver of the CXCR2/CXCR2 ligands cluster in 
adenocarcinomas and is regulated through promoter methylation 
CXCL5 was the gene most upregulated in the CXCR2/CXCR2 ligands cluster in 
comparison to other samples across the whole genome, in both the cell lines and 
lung adenocarcinomas. CXCL5 upregulation was associated with poor overall 
survival (Fig. 16).  
  
Figure 15 
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Figure 16. CXCL5 upregulation and overall survival.  
 
 
Its distribution was bimodal in both cell lines and lung adenocarcinomas (Fig. 
17A and B). This led us to hypothesize that promoter methylation might regulate 
its expression. CXCL5 gene expression was inversely correlated with the 
average beta-value, which measures the degree of methylation of the promoter 
(Fig. 17C). Data generated in an independent study with publicly available raw 
data 55 confirmed high levels of expression of CXCL5 in cell lines included in the 
CXCR2/CXCR2 ligands axis, and low levels in other cell lines, including 
immortalized HBEC lines (Fig. 17D).  
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Figure 17. CXCL5 drives the CXCR2/CXCR2 ligands cluster and is regulated 
through promoter methylation. CXCL5 is the gene most frequently upregulated across 
the whole genome in samples with the CXCR2/CXCR2 ligands cluster compared to 
other samples, both in vitro (A) and in vivo (B). (C) CXCL5 gene expression was 
inversely correlated with the average beta-value, and (D) was increased after treatment 
with decitabine in most of the cell lines with low baseline CXCL5 expression.  
 
 
Figure 17 
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Moreover, CXCL5 expression was induced by decitabine in most of the cell lines 
with low CXCL5 expression that were shown to be methylated, as well as in 
HBEC cells. Expression of CXCL1 (r = -0.46, P=0.0021), CXCL2 (r= -0.49, 
P=0.0010), CXCL3 (r = -0.32, P=0.0390), and CXCL6 (r = -0.46, P=0.0022) 
genes was significantly inversely correlated with the average beta-value of their 
respective promoter, suggesting regulation through promoter methylation (Fig. 
18A-D).  
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Figure 18. Promoter methylation of CXCR2 ligand genes. Expression of (A) CXCL1, 
(B) CXCL2, (C) CXCL3, and (D) CXCL6 genes was negatively correlated with the level 
of their promoter methylation as indicated by average beta-value.  
 
However, only CXCL1 and CXCL3 had patterns similar to CXCL5 in terms of 
response to decitabine (Fig. 19A-D). 
 
Figure 18 
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Figure 19. Effect of decitabine on CXCR2 ligand genes. The effect of two doses of 
decitabine on (A) CXCL1, (B) CXCL2, (C) CXCL3, and (D) CXCL6 gene expression 
levels in 10 lung cell lines is shown.  
 
  
Figure 19 
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DISCUSSION 
We show that in vivo CXCR2 inhibition by knock-down in a murine cell line (344SQ), 
which has a known high metastatic potential, reduces its invasive ability.  In a murine 
model of orthotopic syngeneic lung adenocarcinoma CXCR2 knock-down 344SQ cell 
line was found to be associated with decreased tumor burden, local and distant 
metastases. In order to translate our preclinical discoveries to human NSCLC, we 
explored CXCR2 tumoral immunohistochemical expression in tissue microarrays from 
patients with surgically resected stage I-II lung adenocarcinoma and correlated it with 
patient clinic-pathological characteristics including smoking status, histological 
differentiation and survival outcomes. We considered also localization of CXCR2 
expression in the cytoplasm, membrane and nucleus. High cytoplasmic CXCR2 was 
associated with smoking history, aggressive histological differentiation and worse 
survival. When we screened a publicly available large database of NSCLC cell lines 
and lung adenocarcinomas, we found that at the gene expression level, CXCL5, a 
CXCR2-ligand, was the main driver of a cluster of cell lines and lung adenocarcinomas 
with high-risk features, including RAS and MET pathway activation, epithelial-to-
mesenchimal transition and resistance to epidermal growth factor inhibition (i.e., 
gefitinib). We have named this CXCR2/CXCR2 ligands cluster and we discovered that 
CXCL5 in this cluster was regulated by promoter methylation.  
Several studies have reported a critical role of CXCR2 inhibition in melanoma43; 59, 
ovarian59, prostate60, and esophageal cancers61 mainly by regulating the cell cycle, 
apoptosis and angiogenesis via multiple signaling pathways including PI3K/AKT, NF-
kB, MAPK and STAT3. However, there is not a clear understanding if CXCR2 inhibition 
plays a direct effect on tumoral cells. We have tested our hypothesis using a novel 
orthotopic syngeneic lung cancer metastasis model with preserved immunity via 
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injection of a highly metastatic cell line (344SQ) derived from 
KrasLA1/+p53R172HΔG/+ mice. This murine model reliably represents the 
developmental process of human lung adenocarcinomas29. The effect of CXCR2 
knock-down in shRNA stable clones on the substantial reduction of the thoracic 
tumors, lymphatic and distant metastases, is unlikely due to regulation of angiogenesis. 
In fact, data published showing the effect of CXCR2 knockdown in ovarian cancer cell 
lines on decreasing tumor angiogenesis by VEGF activation, were obtained using 
immunosuppressed murine xenografts tumor models which do not take into 
consideration the interaction between the tumoral cells and the tumor 
microenvironment62.  We understand that our work lacks of a direct evaluation on tumor 
angiogenesis, therefore, we cannot completely rule out a direct effect of CXCR2 
knockdown in the 344SQ cells on tumor angiogenesis. 
When we explored in human NSCLC samples the tumoral cell localization of CXCR2 
by IHC, we observed that only cytoplasmic expression was associated with significant 
difference in terms of smoking history, histologic differentiation and survival. Although 
many chemokine receptors internalize through clathrin-coated pits, regulation of the 
receptor trafficking is not fully understood. Fan GH et al. showed colocalization of 
CXCR2 with transferrin and low-density lipoprotein (LDL) after agonist treatment for 
different periods of time, suggesting 2 intracellular trafficking pathways for this 
receptor. CXCR2 was colocalized with Rab5 and Rab11a, which are localized in early 
and recycling endosomes, respectively, in response to agonist stimulation for a short 
period of time, suggesting a recycling pathway for the receptor trafficking63. The altered 
distribution of CXCR2 into the cytoplasm may start an autocrine loop that may 
contribute as a transcriptional signaling to augment expression of receptor-ligand 
production as previously suggested in prostate cancer progression60. 
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CXCR2 inhibition has been reported to also affect the epithelial to-mesenchymal 
transition via abrogation of the Snail-mediated increase in tumor burden in murine 
models of NSCLC39; 64. However, contrasting results were described on this topic in a 
small cohort of 20 NSCLC showing a correlation between CXCR2 expression and 
improved survival65. In addition, a role of CXCR2 as tumor suppressor gene was also 
underscored in studies about tumor senescence and response to oncogenic signals66. 
Our GSEA analysis results show that c-MET oncogenic pathway is expressed in the 
CXCR2/CXCR2 ligands cluster, which is in line with the observation of downregulation 
of SPINT1, a potent inhibitor specific for HGF activator, and upregulation of TGFB1 
and VIM in the CXCR2/CXCR2 ligands cluster67.  
Another interesting finding of our tissue microarray and GSEA analysis was the 
association of CXCR2 protein expression, the CXCR2/CXCR2 ligands cluster and high 
histological grade. The thyroid transcription factor 1 (TTF1, NKX2-1), which is a lineage 
survival gene abnormally expressed in about 70% of lung adenocarcinoma, was one of 
the genes most frequently downregulated in the cluster compared to other lung 
adenocarcinomas. Interestingly, NKX2-1 protein expression in human NSCLC has 
been reported in the literature to be prevalent in lung adenocarcinoma, female gender, 
non-smoking history, presence of epidermal growth factor receptor (EGFR) mutation 
and better overall survival and it is one of the routinely tested immunohistochemical 
markers for the pathological diagnosis of NSCLC68. Absence of NKX2-1 expression 
may identify lung adenocarcinomas with CXCR2 activation, with interesting 
repercussion on the identification of tumors which may be targeted by CXCR2 
inhibition. In addition, the correlation between NKX2-1 protein expression and 
presence of epidermal growth factor receptor (EGFR) mutation, is in line with the 
findings of absence of EGFR mutations in the lung adenocarcinoma included in the 
43 
 
CXCR2/CXCR2 ligands cluster in the DCC dataset which doesn’t express NKX2-1 
protein. Our findings in the DCC dataset also highlight the association of CXCR2 
expression and KRAS mutation which is indication of EGFR tyrosine kinase inhibitor 
therapy resistance69. These observations are in line with the strong inhibitory effect of 
CXCR2 knockdown in our orthotopic syngeneic lung adenocarcinoma metastasis 
model, which harbors a KRAS mutation. Therefore, CXCR2 may represent an 
important target of KRAS-driven lung adenocarcinomas. 
The findings of CXCL5 being the main driver gene in the CXCR2/CXCR2 ligands 
cluster add to the current literature where there are controversial reports about its 
significance in different tumor types. In head and neck squamous cell carcinoma 
CXCL5 has been associated with tumor cell proliferation, migration and invasion70. On 
the other hand, knock down cell clones of colon carcinoma resulted in a rapid tumor 
growth and in a number of tumor metastases in vivo71. In the same study  low 
expression of CXCL5 by immunohistochemistry was significantly associated with poor 
outcome in human colon cancer patients71. In human lung adenocarcinoma there is no 
data on the association of CXCL5 expression and prognosis. However, in NSCLC 
methylation appears the main mechanism of regulation72. We found that about 75-80% 
of NSCLC harbor CXCL5 promoter methylation with sub sequential silencing of the 
gene. These observations may suggest that CXCL5 might promote tumorigenesis in 
20% of lung adenocarcinomas through CXCR2 autocrine and paracrine loop. 
In conclusion, our data show that tumoral CXCR2 inhibition has an important role on 
regulation of invasion, growth in vitro and in vivo in an orthotopic syngeneic lung 
adenocarcinoma metastasis model with KRAS and TP53 mutations. We identified a 
cluster of human NSCLC cell lines and lung adenocarcinomas, in which prognosis 
seems to be affected by the CXCR2-CXCL5 axis with an interesting association to 
aggressive histology and smoking history. Pharmaceutical inhibition of CXCR2 is 
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currently undergoing clinical development in COPD to counter-act the damaging effects 
of cigarette smoking that produces inflammation with increase in alveolar destruction 
by neutrophils, goblet cell hyperplasia and pro-angiogenetic effects17; 44. In addition, the 
finding of a cluster of lung adenocarcinomas with CXCR-2 ligand overexpression may 
of great value in directing novel approaches in T cell adoptive therapy of lung cancer, 
as showed by Peng W. et al, who introduced the CXCR2 gene into tumor-specific T 
cells to enhance their localization to tumors and improve antitumor immune 
responses73. Therefore, with the future availability of CXCR2 targeted therapy in clinical 
cancer research, CXCR2 expression may become an interesting target to validate in 
prospective clinical trials in NSCLC.  
45 
 
 
BIBLIOGRAPHY 
1. Siegel, R., Naishadham, D. & Jemal, A. (2013). Cancer statistics, 2013. CA 
Cancer J Clin 63, 11-30. 
2. Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., 
Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., Garg, K., 
Austin, J. H., Asamura, H., Rusch, V. W., Hirsch, F. R., Scagliotti, G., Mitsudomi, 
T., Huber, R. M., Ishikawa, Y., Jett, J., Sanchez-Cespedes, M., Sculier, J. P., 
Takahashi, T., Tsuboi, M., Vansteenkiste, J., Wistuba, I., Yang, P. C., Aberle, D., 
Brambilla, C., Flieder, D., Franklin, W., Gazdar, A., Gould, M., Hasleton, P., 
Henderson, D., Johnson, B., Johnson, D., Kerr, K., Kuriyama, K., Lee, J. S., 
Miller, V. A., Petersen, I., Roggli, V., Rosell, R., Saijo, N., Thunnissen, E., Tsao, 
M. & Yankelewitz, D. (2011). International association for the study of lung 
cancer/american thoracic society/european respiratory society international 
multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6, 244-
85. 
3. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., 
Zhu, J. & Johnson, D. H. (2002). Comparison of four chemotherapy regimens for 
advanced non-small-cell lung cancer. N Engl J Med 346, 92-8. 
4. Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., 
Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J. 
S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., de Marinis, F., 
Simms, L., Sugarman, K. P. & Gandara, D. (2008). Phase III study comparing 
cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive 
46 
 
patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26, 3543-
51. 
5. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., 
Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., 
Louis, D. N., Christiani, D. C., Settleman, J. & Haber, D. A. (2004). Activating 
mutations in the epidermal growth factor receptor underlying responsiveness of 
non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-39. 
6. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, 
P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, 
M. J., Sellers, W. R., Johnson, B. E. & Meyerson, M. (2004). EGFR mutations in 
lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 
1497-500. 
7. Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., 
Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., 
Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y. & Mano, H. (2007). 
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung 
cancer. Nature 448, 561-6. 
8. Suda, K., Tomizawa, K., Yatabe, Y. & Mitsudomi, T. (2011). Lung cancers 
unrelated to smoking: characterized by single oncogene addiction? Int J Clin 
Oncol 16, 294-305. 
9. Weinstein, I. B. (2002). Cancer. Addiction to oncogenes--the Achilles heal of 
cancer. Science 297, 63-4. 
10. Pao, W. & Girard, N. (2011). New driver mutations in non-small-cell lung cancer. 
Lancet Oncol 12, 175-80. 
47 
 
11. Paik, P. K., Arcila, M. E., Fara, M., Sima, C. S., Miller, V. A., Kris, M. G., Ladanyi, 
M. & Riely, G. J. (2011). Clinical characteristics of patients with lung 
adenocarcinomas harboring BRAF mutations. J Clin Oncol 29, 2046-51. 
12. Le, Y., Zhou, Y., Iribarren, P. & Wang, J. (2004). Chemokines and chemokine 
receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 1, 
95-104. 
13. Schadendorf, D., Moller, A., Algermissen, B., Worm, M., Sticherling, M. & 
Czarnetzki, B. M. (1993). IL-8 produced by human malignant melanoma cells in 
vitro is an essential autocrine growth factor. J Immunol 151, 2667-75. 
14. Zhu, Y. M., Webster, S. J., Flower, D. & Woll, P. J. (2004). Interleukin-8/CXCL8 
is a growth factor for human lung cancer cells. Br J Cancer 91, 1970-6. 
15. Wang, J. M., Taraboletti, G., Matsushima, K., Van Damme, J. & Mantovani, A. 
(1990). Induction of haptotactic migration of melanoma cells by neutrophil 
activating protein/interleukin-8. Biochem Biophys Res Commun 169, 165-70. 
16. Balkwill, F. (2004). Cancer and the chemokine network. Nat Rev Cancer 4, 540-
50. 
17. Chapman, R. W., Phillips, J. E., Hipkin, R. W., Curran, A. K., Lundell, D. & Fine, 
J. S. (2009). CXCR2 antagonists for the treatment of pulmonary disease. 
Pharmacol Ther 121, 55-68. 
18. Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., 
Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D. & et al. (1995). The 
functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol 
Chem 270, 27348-57. 
19. Addison, C. L., Daniel, T. O., Burdick, M. D., Liu, H., Ehlert, J. E., Xue, Y. Y., 
Buechi, L., Walz, A., Richmond, A. & Strieter, R. M. (2000). The CXC chemokine 
48 
 
receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced 
angiogenic activity. J Immunol 165, 5269-77. 
20. Keane, M. P., Belperio, J. A., Xue, Y. Y., Burdick, M. D. & Strieter, R. M. (2004). 
Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of 
lung cancer. J Immunol 172, 2853-60. 
21. Heidemann, J., Ogawa, H., Dwinell, M. B., Rafiee, P., Maaser, C., Gockel, H. R., 
Otterson, M. F., Ota, D. M., Lugering, N., Domschke, W. & Binion, D. G. (2003). 
Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular 
endothelial cells are mediated by CXCR2. J Biol Chem 278, 8508-15. 
22. Belperio, J. A., Keane, M. P., Burdick, M. D., Gomperts, B., Xue, Y. Y., Hong, K., 
Mestas, J., Ardehali, A., Mehrad, B., Saggar, R., Lynch, J. P., Ross, D. J. & 
Strieter, R. M. (2005). Role of CXCR2/CXCR2 ligands in vascular remodeling 
during bronchiolitis obliterans syndrome. J Clin Invest 115, 1150-62. 
23. Murdoch, C. & Finn, A. (2000). Chemokine receptors and their role in 
inflammation and infectious diseases. Blood 95, 3032-43. 
24. Wang, S., Yue, H., Derin, R. B., Guggino, W. B. & Li, M. (2000). Accessory 
protein facilitated CFTR-CFTR interaction, a molecular mechanism to potentiate 
the chloride channel activity. Cell 103, 169-79. 
25. Wu, Y., Wang, S., Farooq, S. M., Castelvetere, M. P., Hou, Y., Gao, J. L., 
Navarro, J. V., Oupicky, D., Sun, F. & Li, C. (2012). A chemokine receptor 
CXCR2 macromolecular complex regulates neutrophil functions in inflammatory 
diseases. J Biol Chem 287, 5744-55. 
26. Chen, J. J., Yao, P. L., Yuan, A., Hong, T. M., Shun, C. T., Kuo, M. L., Lee, Y. C. 
& Yang, P. C. (2003). Up-regulation of tumor interleukin-8 expression by 
infiltrating macrophages: its correlation with tumor angiogenesis and patient 
survival in non-small cell lung cancer. Clin Cancer Res 9, 729-37. 
49 
 
27. White, E. S., Flaherty, K. R., Carskadon, S., Brant, A., Iannettoni, M. D., Yee, J., 
Orringer, M. B. & Arenberg, D. A. (2003). Macrophage migration inhibitory factor 
and CXC chemokine expression in non-small cell lung cancer: role in 
angiogenesis and prognosis. Clin Cancer Res 9, 853-60. 
28. Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., 
Jacks, T. & Tuveson, D. A. (2001). Analysis of lung tumor initiation and 
progression using conditional expression of oncogenic K-ras. Genes Dev 15, 
3243-8. 
29. Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M. 
& Jacks, T. (2005). The differential effects of mutant p53 alleles on advanced 
murine lung cancer. Cancer Res 65, 10280-8. 
30. Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, 
D. A. & Jacks, T. (2001). Somatic activation of the K-ras oncogene causes early 
onset lung cancer in mice. Nature 410, 1111-6. 
31. Liu, G., McDonnell, T. J., Montes de Oca Luna, R., Kapoor, M., Mims, B., El-
Naggar, A. K. & Lozano, G. (2000). High metastatic potential in mice inheriting a 
targeted p53 missense mutation. Proc Natl Acad Sci U S A 97, 4174-9. 
32. Gibbons, D. L., Lin, W., Creighton, C. J., Zheng, S., Berel, D., Yang, Y., Raso, M. 
G., Liu, D. D., Wistuba, II, Lozano, G. & Kurie, J. M. (2009). Expression 
signatures of metastatic capacity in a genetic mouse model of lung 
adenocarcinoma. PLoS One 4, e5401. 
33. Wislez, M., Fujimoto, N., Izzo, J. G., Hanna, A. E., Cody, D. D., Langley, R. R., 
Tang, H., Burdick, M. D., Sato, M., Minna, J. D., Mao, L., Wistuba, I., Strieter, R. 
M. & Kurie, J. M. (2006). High expression of ligands for chemokine receptor 
CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 
66, 4198-207. 
50 
 
34. Strieter, R. M., Burdick, M. D., Gomperts, B. N., Belperio, J. A. & Keane, M. P. 
(2005). CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 16, 593-
609. 
35. Raghuwanshi, S. K., Nasser, M. W., Chen, X., Strieter, R. M. & Richardson, R. 
M. (2008). Depletion of beta-arrestin-2 promotes tumor growth and angiogenesis 
in a murine model of lung cancer. J Immunol 180, 5699-706. 
36. Burger, M., Burger, J. A., Hoch, R. C., Oades, Z., Takamori, H. & Schraufstatter, 
I. U. (1999). Point mutation causing constitutive signaling of CXCR2 leads to 
transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled 
receptor. J Immunol 163, 2017-22. 
37. Vandercappellen, J., Van Damme, J. & Struyf, S. (2008). The role of CXC 
chemokines and their receptors in cancer. Cancer Lett 267, 226-44. 
38. Sun, H., Chung, W. C., Ryu, S. H., Ju, Z., Tran, H. T., Kim, E., Kurie, J. M. & 
Koo, J. S. (2008). Cyclic AMP-responsive element binding protein- and nuclear 
factor-kappaB-regulated CXC chemokine gene expression in lung 
carcinogenesis. Cancer Prev Res (Phila) 1, 316-28. 
39. Yanagawa, J., Walser, T. C., Zhu, L. X., Hong, L., Fishbein, M. C., Mah, V., Chia, 
D., Goodglick, L., Elashoff, D. A., Luo, J., Magyar, C. E., Dohadwala, M., Lee, J. 
M., St John, M. A., Strieter, R. M., Sharma, S. & Dubinett, S. M. (2009). Snail 
promotes CXCR2 ligand-dependent tumor progression in non-small cell lung 
carcinoma. Clin Cancer Res 15, 6820-9. 
40. Luppi, F., Longo, A. M., de Boer, W. I., Rabe, K. F. & Hiemstra, P. S. (2007). 
Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through 
epidermal growth factor receptor transactivation. Lung Cancer 56, 25-33. 
41. Maxwell, P. J., Gallagher, R., Seaton, A., Wilson, C., Scullin, P., Pettigrew, J., 
Stratford, I. J., Williams, K. J., Johnston, P. G. & Waugh, D. J. (2007). HIF-1 and 
51 
 
NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes 
cell survival in hypoxic prostate cancer cells. Oncogene 26, 7333-45. 
42. Varney, M. L., Singh, S., Li, A., Mayer-Ezell, R., Bond, R. & Singh, R. K. (2010). 
Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer 
liver metastases. Cancer Lett 300, 180-8. 
43. Singh, S., Sadanandam, A., Nannuru, K. C., Varney, M. L., Mayer-Ezell, R., 
Bond, R. & Singh, R. K. (2009). Small-molecule antagonists for CXCR2 and 
CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, 
survival, and angiogenesis. Clin Cancer Res 15, 2380-6. 
44. Johnson, Z., Power, C. A., Weiss, C., Rintelen, F., Ji, H., Ruckle, T., Camps, M., 
Wells, T. N., Schwarz, M. K., Proudfoot, A. E. & Rommel, C. (2004). Chemokine 
inhibition--why, when, where, which and how? Biochem Soc Trans 32, 366-77. 
45. White, J. R., Lee, J. M., Young, P. R., Hertzberg, R. P., Jurewicz, A. J., Chaikin, 
M. A., Widdowson, K., Foley, J. J., Martin, L. D., Griswold, D. E. & Sarau, H. M. 
(1998). Identification of a potent, selective non-peptide CXCR2 antagonist that 
inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273, 10095-8. 
46. Gibbons, D. L., Lin, W., Creighton, C. J., Rizvi, Z. H., Gregory, P. A., Goodall, G. 
J., Thilaganathan, N., Du, L., Zhang, Y., Pertsemlidis, A. & Kurie, J. M. (2009). 
Contextual extracellular cues promote tumor cell EMT and metastasis by 
regulating miR-200 family expression. Genes Dev 23, 2140-51. 
47. Yang, Y., Ahn, Y. H., Gibbons, D. L., Zang, Y., Lin, W., Thilaganathan, N., 
Alvarez, C. A., Moreira, D. C., Creighton, C. J., Gregory, P. A., Goodall, G. J. & 
Kurie, J. M. (2011). The Notch ligand Jagged2 promotes lung adenocarcinoma 
metastasis through a miR-200-dependent pathway in mice. J Clin Invest 121, 
1373-85. 
52 
 
48. Zheng, S., El-Naggar, A. K., Kim, E. S., Kurie, J. M. & Lozano, G. (2007). A 
genetic mouse model for metastatic lung cancer with gender differences in 
survival. Oncogene 26, 6896-904. 
49. Yuan, P., Kadara, H., Behrens, C., Tang, X., Woods, D., Solis, L. M., Huang, J., 
Spinola, M., Dong, W., Yin, G., Fujimoto, J., Kim, E., Xie, Y., Girard, L., Moran, 
C., Hong, W. K., Minna, J. D. & Wistuba, II. (2010). Sex determining region Y-
Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the 
pathogenesis of squamous cell carcinomas of the lung. PLoS One 5, e9112. 
50. Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Bierie, B., Tada, M., Mohri, D., 
Miyabayashi, K., Asaoka, Y., Maeda, S., Ikenoue, T., Tateishi, K., Wright, C. V., 
Koike, K., Omata, M. & Moses, H. L. (2011). Inhibiting Cxcr2 disrupts tumor-
stromal interactions and improves survival in a mouse model of pancreatic ductal 
adenocarcinoma. J Clin Invest 121, 4106-17. 
51. Shedden, K., Taylor, J. M., Enkemann, S. A., Tsao, M. S., Yeatman, T. J., 
Gerald, W. L., Eschrich, S., Jurisica, I., Giordano, T. J., Misek, D. E., Chang, A. 
C., Zhu, C. Q., Strumpf, D., Hanash, S., Shepherd, F. A., Ding, K., Seymour, L., 
Naoki, K., Pennell, N., Weir, B., Verhaak, R., Ladd-Acosta, C., Golub, T., Gruidl, 
M., Sharma, A., Szoke, J., Zakowski, M., Rusch, V., Kris, M., Viale, A., Motoi, N., 
Travis, W., Conley, B., Seshan, V. E., Meyerson, M., Kuick, R., Dobbin, K. K., 
Lively, T., Jacobson, J. W. & Beer, D. G. (2008). Gene expression-based survival 
prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 
14, 822-7. 
52. Lockwood, W. W., Chari, R., Coe, B. P., Girard, L., Macaulay, C., Lam, S., 
Gazdar, A. F., Minna, J. D. & Lam, W. L. (2008). DNA amplification is a 
ubiquitous mechanism of oncogene activation in lung and other cancers. 
Oncogene 27, 4615-24. 
53 
 
53. Zhou, B. B., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y., Baribaud, 
F., Mikami, I., Reguart, N., Yang, G., Li, Y., Yao, W., Vaddi, K., Gazdar, A. F., 
Friedman, S. M., Jablons, D. M., Newton, R. C., Fridman, J. S., Minna, J. D. & 
Scherle, P. A. (2006). Targeting ADAM-mediated ligand cleavage to inhibit HER3 
and EGFR pathways in non-small cell lung cancer. Cancer Cell 10, 39-50. 
54. Raponi, M., Zhang, Y., Yu, J., Chen, G., Lee, G., Taylor, J. M., Macdonald, J., 
Thomas, D., Moskaluk, C., Wang, Y. & Beer, D. G. (2006). Gene expression 
signatures for predicting prognosis of squamous cell and adenocarcinomas of the 
lung. Cancer Res 66, 7466-72. 
55. Shames, D. S., Girard, L., Gao, B., Sato, M., Lewis, C. M., Shivapurkar, N., 
Jiang, A., Perou, C. M., Kim, Y. H., Pollack, J. R., Fong, K. M., Lam, C. L., Wong, 
M., Shyr, Y., Nanda, R., Olopade, O. I., Gerald, W., Euhus, D. M., Shay, J. W., 
Gazdar, A. F. & Minna, J. D. (2006). A genome-wide screen for promoter 
methylation in lung cancer identifies novel methylation markers for multiple 
malignancies. PLoS Med 3, e486. 
56. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, 
M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S. & Mesirov, J. P. 
(2005). Gene set enrichment analysis: a knowledge-based approach for 
interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 
15545-50. 
57. Onn, A., Isobe, T., Itasaka, S., Wu, W., O'Reilly, M. S., Ki Hong, W., Fidler, I. J. & 
Herbst, R. S. (2003). Development of an orthotopic model to study the biology 
and therapy of primary human lung cancer in nude mice. Clin Cancer Res 9, 
5532-9. 
58. Roybal, J. D., Zang, Y., Ahn, Y. H., Yang, Y., Gibbons, D. L., Baird, B. N., 
Alvarez, C., Thilaganathan, N., Liu, D. D., Saintigny, P., Heymach, J. V., 
54 
 
Creighton, C. J. & Kurie, J. M. (2011). miR-200 Inhibits lung adenocarcinoma cell 
invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res 9, 25-35. 
59. Singh, S., Varney, M. & Singh, R. K. (2009). Host CXCR2-dependent regulation 
of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer 
Res 69, 411-5. 
60. Murphy, C., McGurk, M., Pettigrew, J., Santinelli, A., Mazzucchelli, R., Johnston, 
P. G., Montironi, R. & Waugh, D. J. (2005). Nonapical and cytoplasmic 
expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation 
and microvessel density in prostate cancer. Clin Cancer Res 11, 4117-27. 
61. Wang, B., Hendricks, D. T., Wamunyokoli, F. & Parker, M. I. (2006). A growth-
related oncogene/CXC chemokine receptor 2 autocrine loop contributes to 
cellular proliferation in esophageal cancer. Cancer Res 66, 3071-7. 
62. Yang, G., Rosen, D. G., Liu, G., Yang, F., Guo, X., Xiao, X., Xue, F., Mercado-
Uribe, I., Huang, J., Lin, S. H., Mills, G. B. & Liu, J. (2010). CXCR2 promotes 
ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and 
enhanced angiogenesis. Clin Cancer Res 16, 3875-86. 
63. Fan, G. H., Lapierre, L. A., Goldenring, J. R. & Richmond, A. (2003). Differential 
regulation of CXCR2 trafficking by Rab GTPases. Blood 101, 2115-24. 
64. Kuo, P. L., Chen, Y. H., Chen, T. C., Shen, K. H. & Hsu, Y. L. (2010). 
CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition 
of hormone-independent prostate cancer by early growth response-1 /Snail 
signaling pathway. J Cell Physiol. 
65. Ohri, C. M., Shikotra, A., Green, R. H., Waller, D. A. & Bradding, P. (2010). 
Chemokine receptor expression in tumour islets and stroma in non-small cell 
lung cancer. BMC Cancer 10, 172. 
55 
 
66. Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., 
Fumagalli, M., Da Costa, M., Brown, C., Popov, N., Takatsu, Y., Melamed, J., 
d'Adda di Fagagna, F., Bernard, D., Hernando, E. & Gil, J. (2008). Chemokine 
signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-18. 
67. Roussos, E. T., Keckesova, Z., Haley, J. D., Epstein, D. M., Weinberg, R. A. & 
Condeelis, J. S. (2010). AACR special conference on epithelial-mesenchymal 
transition and cancer progression and treatment. Cancer Res 70, 7360-4. 
68. Tang, X., Kadara, H., Behrens, C., Liu, D. D., Xiao, Y., Rice, D., Gazdar, A. F., 
Fujimoto, J., Moran, C., Varella-Garcia, M., Lee, J. J., Hong, W. K. & Wistuba, II. 
(2011). Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: 
implications in lung cancer pathogenesis and prognosis. Clin Cancer Res 17, 
2434-43. 
69. Massarelli, E., Varella-Garcia, M., Tang, X., Xavier, A. C., Ozburn, N. C., Liu, D. 
D., Bekele, B. N., Herbst, R. S. & Wistuba, II. (2007). KRAS mutation is an 
important predictor of resistance to therapy with epidermal growth factor receptor 
tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13, 
2890-6. 
70. Miyazaki, H., Patel, V., Wang, H., Edmunds, R. K., Gutkind, J. S. & Yeudall, W. 
A. (2006). Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer 
Res 66, 4279-84. 
71. Speetjens, F. M., Kuppen, P. J., Sandel, M. H., Menon, A. G., Burg, D., van de 
Velde, C. J., Tollenaar, R. A., de Bont, H. J. & Nagelkerke, J. F. (2008). 
Disrupted expression of CXCL5 in colorectal cancer is associated with rapid 
tumor formation in rats and poor prognosis in patients. Clin Cancer Res 14, 
2276-84. 
56 
 
72. Tessema, M., Klinge, D. M., Yingling, C. M., Do, K., Van Neste, L. & Belinsky, S. 
A. (2010). Re-expression of CXCL14, a common target for epigenetic silencing in 
lung cancer, induces tumor necrosis. Oncogene 29, 5159-70. 
73. Peng, W., Ye, Y., Rabinovich, B. A., Liu, C., Lou, Y., Zhang, M., Whittington, M., 
Yang, Y., Overwijk, W. W., Lizee, G. & Hwu, P. (2010). Transduction of tumor-
specific T cells with CXCR2 chemokine receptor improves migration to tumor and 
antitumor immune responses. Clin Cancer Res 16, 5458-68. 
 
 
  
57 
 
VITA 
Erminia Massarelli was born in Naples, Italy on November 27, 1972, the daughter of 
Cristina Avolio and Luigi Massarelli. After completing her work at Giuseppe Garibaldi 
high school, Naples, Italy, she entered Medical School at the University of Naples 
Federico II, Naples, Italy. She received her medical school degree with summa cum 
laude on July 22, 1997. She then entered the Specialization in Medical Oncology at the 
University of Naples Federico II, and completed her clinical training in October 2001, 
passing the Italian Board of Medical Oncology in October 2001. She entered her PhD 
in Molecular Oncology and Endocrinology in November 2001 at the University of 
Naples Federico II, Naples, Italy where she was included in an international program 
that allowed her to spend the last two years of her research training at MD Anderson 
Cancer Center, Houston, Texas. She received her PhD degree in February 2006. She 
also completed her postdoctoral fellowship in the Department of Thoracic Head and 
Neck Medical Oncology at MD Anderson Cancer Center, Houston, Texas in July 2007. 
She then enrolled into the Internal Medicine Residency program at the Methodist 
Hospital, Houston Texas and completed her training in July 2009. Dr. Massarelli 
passed the ABIM board certification in Internal Medicine in August 2010. Subsequently 
she entered the clinical Medical Oncology Fellowship program at MD Anderson Cancer 
Center, Houston, Texas in July 2009 and completed her clinical training in July 2012. In 
August 2011 she entered The University of Texas Health Science Center at Houston 
Graduate School of Biomedical Sciences. Dr. Massarelli passed the ABIM board 
certification in Medical Oncology in October 2012. Since November 2012 she holds an 
Assistant Professor position in the Department of Thoracic Head and Neck Medical 
Oncology at MD Anderson Cancer Center, Houston, Texas. 
